Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 D835V||Advanced Solid Tumor||sensitive||FLT3 Inhibitor||MRX-2843||Preclinical - Cell culture||Actionable||In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835V in culture (PMID: 27158668).||27158668|
|FLT3 D835V||hematologic cancer||predicted - sensitive||FLT3 Inhibitor||HQP1351||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing FLT3 D835V demonstrated decreased proliferation in response to GZD824 (HQP1351) in culture, but were less sensitive to treatment than cells expressing other FLT3 kinase domain mutations (PMID: 32247263).||32247263|
|FLT3 D835V||Advanced Solid Tumor||resistant||FLT3 Inhibitor||Pexidartinib||Preclinical||Actionable||In a preclinical study, transformed cells expressing FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).||25847190|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|